CHAMP: Study of NVK-002 in Children With Myopia
Public ClinicalTrials.gov record NCT03350620. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Stage 1: To evaluate the safety and efficacy of 2 concentrations of NVK-002 compared to Vehicle (placebo) for slowing the progression of myopia in children over a 3 year treatment period. Stage 2: To observe safety and efficacy in subjects re-randomized to one (1) year of treatment with NVK-002 or Vehicle following 3 years of treatment in children with progressive myopia.
Study identification
- NCT ID
- NCT03350620
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 670 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 3 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 19, 2017
- Primary completion
- Sep 6, 2022
- Completion
- Oct 18, 2023
- Last update posted
- Nov 26, 2024
2017 – 2023
United States locations
- U.S. sites
- 20
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site #009 | Tucson | Arizona | 85711 | — |
| Site #015 | Berkeley | California | 94720 | — |
| Site #003 | Fullerton | California | 92831 | — |
| Site #016 | San Diego | California | 92129 | — |
| Site #005 | Danbury | Connecticut | 06810 | — |
| Site #004 | Maitland | Florida | 32751 | — |
| Site #024 | Peoria | Illinois | 61615 | — |
| Site #006 | Boston | Massachusetts | 02115 | — |
| Site #014 | St Louis | Missouri | 63110 | — |
| Site #002 | New York | New York | 10036 | — |
| Site #013 | Raleigh | North Carolina | 27603 | — |
| Site #001 | Columbus | Ohio | 43210 | — |
| Site #018 | Forest Grove | Oregon | 97116 | — |
| Site #011 | Elkins Park | Pennsylvania | 19027 | — |
| Site #017 | Lancaster | Pennsylvania | 17601 | — |
| Site #008 | Memphis | Tennessee | 38104 | — |
| Site #007 | San Antonio | Texas | 78240 | — |
| Site #012 | Kirkland | Washington | 98034 | — |
| Site #020 | Spokane | Washington | 99204 | — |
| Site #021 | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03350620, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 26, 2024 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03350620 live on ClinicalTrials.gov.